SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-23-074145
Filing Date
2023-09-06
Accepted
2023-09-06 08:30:18
Documents
13
Period of Report
2023-08-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 8-K ea184720-8ka1_abvcbio.htm   iXBRL 8-K/A 26817
2 AMENDMENT TO COOPERATION AGREEMENT ea184720ex10-1_abvcbio.htm EX-10.1 26950
  Complete submission text file 0001213900-23-074145.txt   232749

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE abvc-20230817.xsd EX-101.SCH 3030
4 XBRL LABEL FILE abvc-20230817_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE abvc-20230817_pre.xml EX-101.PRE 22369
7 EXTRACTED XBRL INSTANCE DOCUMENT ea184720-8ka1_abvcbio_htm.xml XML 3330
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

IRS No.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-40700 | Film No.: 231237914
SIC: 2834 Pharmaceutical Preparations